Abstract
The standard treatment for epithelial ovarian cancer (EOC) consists
of optimal #cytoreductivesurgery followed by platinum-based#chemotherapy [1-2]. #Bevacizumab has been approved for the treatment
of several tumors such as #colorectal cancer, non-squamous
non-small cell lung cancer, renal cell carcinoma, epithelial ovarian,
#fallopian tube, and primary peritoneal cancers. The use of #antiangiogenic agent in EOC is based on the results of randomized clinical
trials which revealed an improved survival rates with the addition
of bevacizumab to standard first-line #chemotherapeuticdrugs [3-
4].
For more articles on BJSTR Journal please click here: https://biomedres.us/
For more Biomedical Imaging Articles on BJSTR
The #Antiangiogenic Therapy in Ovarian Cancer by Vera Loizzi in BJSTR
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.